



ANALGESIC NEPHROPATHY

RMA ID Number	Reference List for RMA028-2 as at October 2016
---------------	--

44220	Bach PH, Thanh NTK (1998). Renal papillary necrosis-40 years on. <i>Toxicologic Pathology</i> , 26(1) pp 73-91.
44379	Balasubramaniam J (2000). Selective COX-2 inhibitors and nephrotoxicity. <i>American Journal of Kidney Diseases</i> , 36(3) pp 675-676.
44063	Barrett BJ (1996). Acetaminophen and adverse chronic renal outcomes: an appraisal of the epidemiologic evidence. <i>Am J Kidney Dis</i> , 28(1) Suppl 1 pp S14-S19.
78381	Beck LH, Salant DJ (2015). Tubulointerstitial diseases of the kidney. <i>Harrison's Principles of Internal Medicine</i> , 19th edition, Ch 340. .
43969	Bennett WM, Porter GA (1998). Analgesic nephropathy and the use of nonsteroidal anti-inflammatory drugs in renal patients: new insight. <i>Journal of Nephrology</i> , 11(2): 70-75.
45464	Bennett WM; Feinstein AR et al (2001). [Letters] Relationship between nonphenacetin combined analgesics and nephropathy. <i>Kidney International</i> , Vol 60 pp 2039.
43957	Blowey DL (2005). Nephrotoxicity of over-the-counter analgesics, natural medicines, and illicit drugs. <i>Adolescent Medicine Clinics</i> , 16(1) pp 31-43.
44066	Braden GL, O'Shea MH, Mulhern JG (2005). Core curriculum in nephrology. Tubulointerstitial diseases. <i>Am J Kidney Dis</i> , 46(3) pp 560-572.
44065	Brunner FP, Selwood NH (1994). End-stage renal failure due to analgesic nephropathy, its changing pattern and cardiovascular mortality. <i>Nephrol Dial Transplant</i> , 9(10) pp 1371-1376.
399	Burrell JH, Yong JLC, Macdonald GJ (1991). Analgesic nephropathy in Fischer 344 rats: Comparative effects of chronic treatment with either aspirin or paracetamol. <i>Pathology</i> , 23: 107-14.
44875	Campo A; Thurlow W; Fored CM, Nyren O (2002). Acetaminophen, aspirin, and renal failure. <i>NEJM</i> , 346(20) pp 1588-1589.
78382	Chang SH, Mathew TH, McDonald SP (2008). Analgesic nephropathy and renal replacement therapy in Australia: trends, comorbidities and outcomes. <i>Clin J Am Soc Nephrol</i> , 3(3): 768-76.
44874	Chogle AR (2003). Screening patients on long term non-steroidal anti-inflammatory drugs (NSAIDs) for nephrotoxicity - why necessary and how frequently? <i>JAPI</i> , Vol 51 pp 1041-1042.
44054	Curhan GC, Knight EL, Rosner B, Hankinson SE, Stampfer MJ (2004). Lifetime nonnarcotic analgesic use and decline in renal function in women. <i>Arch Intern Med</i> , 164(14) pp 1519-1524.
44069	Cuzzolin L, Dal Cere M, Fanos V (2001). NSAID-induced nephrotoxicity from the fetus to the child. <i>Drug Safety</i> , 24(1) pp 9-18.

78045	De Broe ME (2015). Analgesic-related chronic kidney disease. Retrieved 27 April 2016, from http://www.uptodate.com/contents/analgesic-related-chronic-kidney-disease
78044	De Broe ME (2016). Clinical manifestations and diagnosis of analgesic nephropathy. Retrieved 27 April 2016, from http://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-analgesic-nephropathy
78048	De Broe ME, Elseviers MM (2009). Over-the-counter analgesic use. <i>J Am Soc Nephrol</i> , 20: 2098-103.
44062	Delzell E, Shapiro S (1996). Commentary on the National Kidney Foundation position paper on analgesics and the kidney. [Letter] <i>Am J Kidney Dis</i> , 28(5) pp 783-785.
44067	Delzell E, Shapiro S (1998). A review of epidemiologic studies of nonnarcotic analgesics and chronic renal disease. <i>Medicine</i> , 77(2) pp 102-121.
45283	Derby LE, Jick H (1991). Renal parenchymal disease related to over-the-counter analgesic use. <i>Pharmacotherapy</i> , 11(6) pp 467-471.
78463	Dorland (2012). Analgesic nephropathy. <i>Dorland's Illustrated Medical Dictionary</i> , 32nd Edition: 1241. Elsevier Saunders, Philadelphia.
44061	Duggin GG (1996). Combination analgesic-induced kidney disease: the Australian experience. <i>Am J Kidney Dis</i> , 28(1) Suppl 1 pp S39-S47.
44378	Dunn MJ (2000). Are COX-2 selective inhibitors nephrotoxic? <i>American Journal of Kidney Diseases</i> , 35(5) pp 976-977.
44374	Elseviers MM, De Broe ME (1997). Epidemiology of toxic nephropathies. <i>Adv Nephrol Necker Hosp</i> , Vol 27 pp 241-262.
44068	Elseviers MM, De Broe ME (1999). Analgesic nephropathy. Is it caused by multi-analgesic abuse or single substance abuse? <i>Drug Safety</i> , 20(1) pp 15-24.
45465	Elseviers MM, De Schepper A, Corthouts R, Bosmans J-L, et al (1995). High diagnostic performance of CT scan for analgesic nephropathy in patients with incipient to severe renal failure. <i>Kidney International</i> , Vol 48 pp 1316-1323.
44226	Elseviers MM, et al; Nanra RS; Lornoy W, et al; Pommer W, et al (2001). [Letters] Relationship between nonphenacetin-combined analgesics and nephropathy. <i>Kidney International</i> , 59(6) pp 2370-2373.
44060	Elseviers MM, Waller I, Nenov D, Levora J, Matousovic K, Tanquerel T, et al (1995). Evaluation of diagnostic criteria for analgesic nephropathy in patients with end-stage renal failure: results of the ANNE study. <i>Nephrol Dial Transplant</i> , 10(6) pp 808-814.
44375	Enck RE (2006). Opioid safety. <i>Journal of Opioid Management</i> , 2(4) pp 183.
44047	Eras J, Perazella MA (2001). NSAIDs and the kidney revisited: are selective cyclooxygenase-2 inhibitors safe? <i>Am J Med Sci</i> , 321(3) pp 181-190.
78384	Evans M, Forel CM, Bellocco R, et al (2009). Acetaminophen, aspirin and progression of advanced chronic kidney disease. <i>Nephrol Dial Transplant</i> , 24: 1908-18.
45466	Feinstein AR, Heinemann LA, Curhan GC, Delzell E, et al (2000). Relationship between nonphenacetin combined analgesics and nephropathy: a review. <i>Ad Hoc Committee of the International Study Group on Analgesics and Nephropathy. Kidney Int</i> , 58(6) pp 2259-64.
45463	Forel CM, Ejerblad E, Lindblad P, Fryzek JP, et al (2001). Acetaminophen, aspirin, and chronic renal failure. <i>NEJM</i> , 345(25) pp 1801-1808.
44873	Fox J, et al (1996). [Letter] No proof for a particular role of combination analgesics causing end-stage renal failure. <i>Nephrol Dial Transplant</i> , Vol 11 pp 2519-2525.
45462	Fox JM (1999). [Letters] Doubts about a particularly high nephrotoxicity of combination analgesics. <i>Nephrol Dial Transplant</i> , Vol 14 pp 2966-7.

44074	Fox JM, Siebers U (2003). Caffeine as a promoter of analgesic-associated nephropathy - where is the evidence? <i>Fundamental & Clinical Pharmacology</i> , 17(3) pp 377-392.
44058	Gault MH, Barrett BJ (1998). Analgesic nephropathy, <i>Am J Kidney Dis</i> , 32(3) pp 351-360.
44129	Gooch K, Culleton BF, Manns BJ, Zhang J, et al (2007). NSAID use and progression of chronic kidney disease. <i>The American Journal of Medicine</i> , 120(3) pp 280e1-280e7.
44380	Graham MG (2001). Acute renal failure related to high-dose celecoxib. <i>Annals of Internal Medicine</i> , 135(1) pp 69-70.
44376	Gupta K, Weber ML (2006). Renal effects of opioid exposure: considerations for therapeutic use. <i>Journal of Opioid Management</i> , 2(4) pp 236-240.
406	Hartman GW, Torres VE, Leago GF, Williamson B Jr, et al (1984). Analgesic-associated nephropathy. Pathophysiological and Radiological correlation. <i>JAMA</i> , 251(13): 1734-8.
45461	Heinemann LAJ, Garbe E, Lewis M, van der Woude F, Graf H (2005). Case-control study on analgesics and nephropathy (SAN): protocol. <i>BMC Nephrology</i> , 6(9) pp 1-13.
44070	Henrich WL, Agodoa LE, Barrett B, Bennett WM, et al (1996). National Kidney Foundation position paper. Analgesics and the kidney: summary and recommendations to the scientific advisory board of the national kidney foundation from an ad hoc committee of the national kidney foundation. <i>Am J Kidney Dis</i> , 27(1) pp 162-165.
45460	Henrich WL, Clark RL, Kelly JP, Buckalew VM, et al (2006). Non-contrast-enhanced computerized tomography and analgesic-related kidney disease: Report of the National Analgesic Nephropathy Study. <i>J Am Soc Nephrol</i> , Vol 17 pp 1472-4780.
398	Hostetter TH, Brenner BM (1994). Tubulointerstitial diseases of the kidney. <i>Harrison's Principles of Internal Medicine</i> , 13th Edition, Chapter 242: 1314-5. .
44219	Hoy W (2006). Lessons in ethnoephrology. <i>Kidney International</i> , Vol 70 pp 251-257.
65005	IARC Working Group (2012). Phenacetin. Vol 100A: 379-400. Retrieved 12 September 2012, from http://monographs.iarc.fr/ENG/Monographs/vol100A/mono100A-25.pdf
78383	IARC Working Group (2012). Phenacetin. <i>Pharmaceuticals</i> . IARC Monographs on the evaluation of carcinogenic risks to humans, Vol100A: 377-8.
44057	Ibanez L, Morlans M, Vidal X, Martinez MJ, Laporte JR (2005). Case-control study of regular analgesic and nonsteroidal anti-inflammatory use and end-stage renal disease. <i>Kidney International</i> , 67(6) pp 2393-2398.
78049	Ingrasciotta Y, Sultana J, Giorgianni F, et al (2015). Association of individual non-steroidal anti-inflammatory drugs and chronic kidney disease: a population-based case control study. <i>PLoS One</i> , 10(4): e0122899.
78047	Izzedine H, Gueutin V (2016). Drug-induced chronic tubulointerstitial nephritis. Chapter 87. <i>Oxford Textbook of Clinical Nephrology</i> , 4th Edition,: p695-7. .
78043	Jaipaul N (2016). Analgesic nephropathy. . Retrieved 27 April 2016, from https://www.msdmanuals.com/en-au/professional/genitourinary-disorders/tubulointerstitial-diseases/analgesic-nephropathy
78380	Jaipaul N (2016). Tubulointerstitial nephritis. . Retrieved 24 May 2016, from http://www.msdmanuals.com/en-au/professional/genitourinary-disorders/tubulointerstitial-diseases/tubulointerstitial-nephritis
79033	Kankuri E, Solatunturi E, Vapaatalo H (2003). Effects of phenacetin and its metabolite p-phenetidine on COX-1 and COX-2 activities and expression in vitro. <i>Thromb Res</i> , 110: 299-303.
79113	Kato H, Fujigaki Y, Inoue R, et al (2014). Therapeutic dose of acetaminophen as a possible risk factor for acute kidney injury: learning from two healthy young adult cases. <i>Intern Med</i> , 53: 1531-4.

78050	Kelkar M, Cleves MA, Foster HR, et al (2012). Acute and chronic acetaminophen use and renal disease: a case-control study using pharmacy and medical claims. <i>J Manag Care Pharm</i> , 18(3): 234-46.
78051	Khan YH, Sarriff A, Khan AH, et al (2014). Analgesic nephropathy: a neglected cause of chronic kidney disease. <i>Journal of Applied Pharmaceutical Sci</i> , 4(8): 077-9.
44075	Knights KM, Tsoutsikos P, Miners JO (2005). Novel mechanisms of nonsteroidal anti-inflammatory drug-induced renal toxicity. <i>Expert Opin Drug Metab Toxicol</i> , 1(3) pp 399-408.
44053	Kovacevic L, Bernstein J, Valentini RP, Imam A, Gupta N, Mattoo TK (2003). Renal papillary necrosis induced by naproxen. <i>Pediatr Nephrol</i> , 18(8) pp 826-829.
78379	Kuo H-W, Tsai S-S, Tiao M-M, et al (2010). Analgesic use and the risk for progression of chronic kidney disease. <i>Pharmacoepidemiol Drug Saf</i> , 19: 745-51.
44055	Kurth T, Glynn RJ, Walker AM, Rexrode KM, Buring JE, et al (2003). Analgesic use and change in kidney function in apparently healthy men. <i>Am J Kidney Dis</i> , 42(2) pp 234-244.
44072	Lipton RB, Raskin N, Ruoff G, Saper J, Sheftell F, Solomon S (1996). Over-the-counter analgesics and kidney disease [Letter]. <i>Am J Kidney Dis</i> , 27(6) pp 917. Author reply pp 918.
44224	Lipworth L, Friis S, Mellemkjaer L, Signorello LB, et al (2003). A population-based cohort study of mortality among adults prescribed paracetamol in Denmark. <i>Journal of Clinical Epidemiology</i> , 56(8) pp 796-801.
78046	Longo DL, Fauci AS, Kasper DL, et al (2013). Renal tubular disease. Chapter 153. <i>Harrison's Principles of Internal Medicine</i> , 18th Edition.
44221	Lornoy W, Because I, Billiow JM, Sierens L (1998). Analgesic Nephropathy: Clinical Features and Pathogenesis. Original data on the incidence and prevalence in a single renal unit. <i>Acta Clinica Belgica</i> , 53(5) pp 311-318.
44130	Lornoy W, Because I, Billiow JM, Sierens L (2001). [Letter] Relationship between nonphenacetin-combined analgesics and nephropathy. <i>Kidney International</i> , 59(6) pp 2371-2372.
45457	MacKinnon B, Boulton-Jones M, McLaughlin K (2003). Analgesic-associated nephropathy in the West of Scotland: a 12-year observational study. <i>Nephrol Dial Transplant</i> , Vol 18 pp 1800-1805.
401	Mann JEE, Goerig M, Brune K, Luft EC (1993). Ibuprofen as an over-the counter drug: is there a risk for renal injury? <i>Clin Nephrol</i> , 39(1): 1-6.
44073	Markowitz GS, Perazella MA (2005). Drug-induced renal failure: a focus on tubulointerstitial disease. <i>Clin Chim Acta</i> 351(1-2) pp 31-47.
45038	McLaughlin JK, Lipworth L, Chow W-H, Blot WJ (1998). Analgesic use and chronic renal failure: a critical review of the epidemiologic literature. <i>Kidney International</i> , Vol 54 pp 679-686.
78385	Michielsen P (2007). In memoriam 'analgesic nephropathy' (circa 1972-2006). <i>Nephrol Dial Transplant</i> , 22: 999-1001.
44071	Michielsen P, De Schepper P (1996). Analgesic nephropathy in Belgium: confusion between prevalence and incidence [Letter]. <i>Am J Kidney Dis</i> , 28(6) pp 958-959. Author reply pp 960-962.
78052	Michielsen P, Heinemann L, Mihatsch M, et al (2009). Non-phenacetin analgesics and analgesic nephropathy. <i>Nephrol Dial Transplant</i> , 24: 1253-9.
43968	Michielsen P; Baumeister M; Fox JM; Thurlow W; De Broe ME (1998). Analgesic Nephropathy. <i>NEJM</i> , 339(1) pp 48-50
44372	Mihatsch MJ, Khanlari B, Brunner FP (2006). Obituary to analgesic nephropathy-an autopsy study. <i>Nephrol Dial Transplant</i> , Vol 21 pp 3139-3145.
400	Murray MD, Brater CD (1993). Renal Toxicity of the nonsteroidal anti-inflammatory drugs. <i>Annu Rev Pharmacol Toxicol</i> , 32: 435-65.
402	Nanra RJ (1993). Analgesic nephropathy in the 1990s - An Australian perspective. <i>Kidney Int Suppl</i> , 44(42): S86-S92.

79114	Nanra RS (1980). Clinical and pathological aspects of analgesic nephropathy. <i>Br J Clin Pharmacol</i> , 10: 359S-68S.
44225	Nanra RS, Stuart-Taylor J, de Leon AH, White KH (1978). Analgesic nephropathy: etiology, clinical syndrome, and clinicopathologic correlations in Australia. <i>Kidney International</i> , 13(1) pp 79-92.
79115	National Institute of Diabetes and Digestive and Kidney Diseases (2007). Analgesic nephropathy (painkillers and the kidneys). U.S. Dept. of Health and Human Services Pub.
43966	Nelson EB; Horowitz RS; Perneger TV, Whelton PK (1995). [Letters] Kidney failure and analgesic drugs. <i>NEJM</i> , 332(22) pp 1514-1516.
78053	Okafor UH, Unuigbo EI, Onwuchekwa AC, et al (2012). Analgesic nephropathy as a cause of end-stage renal disease in a 55 year-old Nigerian. <i>Niger J Clin Pract</i> , 15(2): 231-4.
47228	Ozkalemkas F, Ali R, Ozkan A, Ozcelik T, Ozkocaman V, et al (2004). Tuberculosis presenting as immune thrombocytopenic purpura. <i>Ann Clin Microbiol Antimicrob</i> , Vol 3: 16.
403	Paller MS (1990). Drug-induced Nephropathies. <i>Med Clin North Am</i> , 74(4): 909-17.
44245	Parente F, Pastore L, Bargiggia S, Cucino C, et al (2007). Incidence and risk factors for gallstones in patients with inflammatory bowel disease: a large case-control study. <i>Hepatology</i> , 45(5) pp 1267-1274.
43970	Perazella MA (2003). Drug-induced renal failure: update on new medications and unique mechanisms of nephrotoxicity. <i>Am J Med Sci</i> , 325(6) pp 349-362.
44059	Perazella MA (2005). Drug-induced nephropathy: an update. <i>Expert Opin Drug Saf</i> , 4(4) pp 689-706.
44377	Perazella MA, Eras J (2000). Are selective COX-2 inhibitors nephrotoxic? <i>American Journal of Kidney Diseases</i> , 35(5) pp 937-940.
43965	Perneger TV, Whelton PK, Klag MJ (1994). Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs. <i>NEJM</i> , 331(25) pp 1675-1679.
45458	Pinter I, Matyus J, Czegany Z, Harsanyi J, et al (2004). Analgesic nephropathy in Hungary: the HANS study. <i>Nephrol Dial Transplant</i> , 19(4) pp 840-843.
407	Pommer W, Bronder E, Greiser E, Helmert U, et al (1989). Regular Analgesic intake and the risk of end-stage renal failure. <i>Am J Nephrol</i> , 9(5): 403-12.
44417	Pommer W, Greiser E (2001). Relationship between nonphenacetin-combined analgesics and nephropathy. <i>Kidney International</i> , 59(6) pp 2372-2373.
44222	Pospishil YO, Antonovych TM (1998). NSAIDs associated nephropathy. <i>Pol J Pathol</i> , 49(1) pp 35-39.
404	Rahman A, Segasothy M, Samad SA, Zulfiqar A, et al (1993). Analgesic use and chronic renal disease in patients with headache. <i>Headache</i> , 33(8): 442-5.
44223	Rastegar A, Kashgarian M (1999). Long-term analgesic use and renal disease. <i>Kidney Int</i> , 55(2) pp 743.
45459	Rexrode KM, Buring JE, Glynn RJ, Stampfer MJ, et al (2001). Analgesic use and renal function in men. <i>JAMA</i> , 286(3) pp 315-321.
43967	Ronco PM (1994). Drug-induced end-stage renal disease. <i>NEJM</i> , 331(25) pp 1711-1712.
44049	Sandhu GK, Heyneman CA (2004). Nephrotoxic potential of selective cyclooxygenase-2 inhibitors. <i>Ann Pharmacother</i> , Vol 38 pp 700-704.
44052	Sandler DP, Burr FR, Weinberg CR (1991). Nonsteroidal anti-inflammatory drugs and the risk for chronic renal disease. <i>Annals of Internal Medicine</i> , 115(3) pp 165-172.
44050	Sandler DP, Smith JC, Weinberg CR, Buckalew VM Jr, Dennis VW, Blythe WB, Burgess WP (1989). Analgesic use and chronic renal disease. <i>N Engl J Med</i> , 320(19) pp 1238-1243.

43964	Sandler DP, Smith JC, Weinberg CR, Buckalew VM, et al (1989). [Abstract] Analgesic use and chronic renal disease. <i>NEJM</i> , 320(19) pp 1238-1243.
405	Schaeffer AJ, Del Greco F (1992). Analgesic Nephropathy. PC Walsh, AB Retik, TA Stamey, ED Vaughan (Ed). <i>Campbell's Urology</i> , 6th Edition,: 2077-8. WB Saunders Co, Philadelphia.
44373	Schnuelle P, van der Woude FJ (2003). [Letters] Analgesics and renal disease in the postphenacetin era. <i>American Journal of Kidney Diseases</i> , 42(2) pp 385-387.
44056	Schnuelle, P, van der Woude FJ (2003). Analgesics and renal disease in the postphenacetin era. [Letter] <i>Am J Kidney Dis</i> , 42(2) pp 385-387.
45456	Schwarz S, Preuschhof L, Zellner D (1999). Incidence of analgesic nephropathy in Berlin since 1983. <i>Nephrol Dial Transplant</i> , Vol 14 pp 109-112.
44048	Segasothy M, Chin GL, Sia KK, Zulfiqar A, Samad SA (1995). Chronic nephrotoxicity of anti-inflammatory drugs used in the treatment of arthritis. <i>British Journal of Rheumatology</i> , 34(2) pp 162-165.
45387	Segasothy M, et al (1993). Renal dysfunction and renal papillary necrosis with long-term use of NSAIDs as a sole or predominant analgesic: A new form of analgesic nephropathy. <i>J Am Soc Nephrol</i> , Vol 4 pp 759.
44064	Segasothy M, Samad SA, Zulfigar A, Bennett WM (1994). Chronic renal disease and papillary necrosis associated with the long-term use of nonsteroidal anti-inflammatory drugs as the sole or predominant analgesic. <i>Am J Kidney Dis</i> , 24(1) pp 17-24.
44228	Siveke JT, Egert J, Sitter T, Schiemann, et al (2004). 5-ASA therapy and renal function in inflammatory bowel disease. <i>Am J Gastroenterol</i> , 100(2): 501.
78054	Stefanovic V (2002). Analgesic nephropathy, Balkan endemic nephropathy and Chinese herbs nephropathy: separate tubulointerstitial kidney disease associated with urothelial malignancy. <i>Medicine and Biology</i> , 9(1): 1-6.
78773	Stonebridge P (2006). <i>Surgery: an Oxford core text</i> . 1.3 Colorectal and perianal disorders. Oxford University Press: 48. .
45455	Study Group on Analgesics and Nephropathy (SAN). Obtained from: http://www.san-project.com
78055	van der Woude FJ, Heinemann LA, Graf H, et al (2007). Analgesics use and ESRD in younger age: a case-control study. <i>BMC Nephrology</i> , 8: 15.
44227	Van Staa TP, Travis S, Leufkens GM, Logan RF (2004). 5-aminosalicylic acids and the risk of renal disease: a large British epidemiologic study. <i>Gastroenterology</i> , 126(7) pp 1733-1739.
78056	Waddington F, Naunton M, Thomas J (2015). Paracetamol and analgesic nephropathy: are you kidneying me? <i>Medical Case Reports Journal</i> , 8: 1-5.
79116	Watanabe A, Fukami T, Takahashi S, et al (2010). Arylacetamide deacetylase is a determinant enzyme for the difference in hydrolase activities of phenacetin and acetaminophen. <i>Drug Metabolism and Disposition</i> , 38(9): 1532-7.
44051	Whelton A (1999). Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. <i>Am J Med</i> , 106(5B) pp 13S-24S.
44622	Whiting PH, Tisocki K, Hawksworth GM (1999). Human renal medullary interstitial cells and analgesic nephropathy. <i>Renal Failure</i> , 21(3&4) pp 387-392.